Pharmacogenetic application in drug development and clinical trials.

Pharmacogenetics examines the genetic characteristics of individuals to understand variations in response to therapeutics. This approach has the potential to significantly affect the development of new medicines. The application of pharmacogenetic principles could yield significant time and resource savings within the drug development process. In preclinical drug development, pharmacogenetics could be applied to compound screening and identifying potential side effects before entering full clinical testing. Subpopulations of patients with different drug responses and underlying genetic markers could be stratified in clinical trials by analyzing their genotype. These data can improve clinical trial design and offer the possibility of optimized drug prescription based on patient genotype. Pharmacogenetics can guide the development of therapeutic interventions by identifying nonresponder patient groups. Advances in high-throughput genotyping technologies have added potential by facilitating the technical hurdles and improving drug development strategies, clinical trial design, and postmarket pharmaco-vigilance. Pharmacogenetics, thus, impacts all phases of drug development and will fundamentally change the practice of medicine in the near future.

[1]  M. Bleavins,et al.  Technologies for detecting genetic polymorphisms in pharmacogenomics. , 1999, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

[2]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[3]  M. Bleavins,et al.  High throughput genotyping for the detection of a single nucleotide polymorphism in NAD(P)H quinone oxidoreductase (DT diaphorase) using TaqMan probes. , 1999, Molecular pathology : MP.

[4]  M. Catalano.  The challenges of psychopharmacogenetics. , 1999, American journal of human genetics.

[5]  S. Shak.  Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. , 1999, Seminars in oncology.

[6]  Nicholas Schork,et al.  Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment , 1999, Nature Genetics.

[7]  A. Di Rienzo,et al.  Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.

[8]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[9]  E. Smeraldi,et al.  Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine , 1998, Molecular Psychiatry.

[10]  E. Vesell,et al.  Genetic Variation as a Guide to Drug Development , 1998, Science.

[11]  J W Jukema,et al.  The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. , 1998, The New England journal of medicine.

[12]  R. Erickson,et al.  Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. , 1997, The Journal of clinical investigation.

[13]  J. Johnson,et al.  Influence of race or ethnicity on pharmacokinetics of drugs. , 1997, Journal of pharmaceutical sciences.

[14]  P. Amouyel,et al.  APOE genotyping and response to drug treatment in Alzheimer's disease , 1997, The Lancet.

[15]  R. Prough,et al.  Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. , 1997, Clinical chemistry.

[16]  R. Maynard,et al.  The Pharmacological Basis of Therapeutics. 9th ed , 1997 .

[17]  K. Lesch,et al.  Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region , 1996, Science.

[18]  W. Trager,et al.  Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. , 1996, Archives of biochemistry and biophysics.

[19]  S. Fihn,et al.  The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin , 1996, Annals of Internal Medicine.

[20]  P. Watkins,et al.  Genetic predisposition to drug-induced liver disease. , 1995, Gastroenterology clinics of North America.

[21]  K. Livak,et al.  Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. , 1995, PCR methods and applications.

[22]  S. Green,et al.  Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. , 1995, The Journal of clinical investigation.

[23]  L. Wienkers,et al.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. , 1994, Pharmacogenetics.

[24]  J. Goldstein,et al.  Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. , 1993, Biochemical and biophysical research communications.

[25]  B. Bain.  Factors affecting the maintenance dose of warfarin. , 1993, Journal of clinical pathology.

[26]  I. Patel,et al.  High clearance of (S)-warfarin in a warfarin-resistant subject. , 1993, British journal of clinical pharmacology.

[27]  S. Liggett,et al.  Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. , 1993, American journal of respiratory cell and molecular biology.

[28]  S. Thompson,et al.  Factors affecting the maintenance dose of warfarin. , 1992, Journal of clinical pathology.

[29]  U. Meyer.  Genetic polymorphisms of drug metabolism * , 1990, Progress in liver diseases.

[30]  G. H. Bush,et al.  Pharmacogenetics , 1968 .

[31]  N. Stollman,et al.  The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review. , 2000, Journal of clinical gastroenterology.

[32]  M. Bleavins,et al.  High-throughput genotyping method for glutathione S-transferase T1 and M1 gene deletions using TaqMan probes. , 1999, Research communications in molecular pathology and pharmacology.

[33]  M J Cupp,et al.  Cytochrome P450: new nomenclature and clinical implications. , 1998, American family physician.

[34]  R. Clegg.  Fluorescence resonance energy transfer and nucleic acids. , 1992, Methods in enzymology.

[35]  W. Kalow.  Pharmacogenetics of drug metabolism , 1980 .